About The Study: In this economic evaluation of extended-release buprenorphine compared with transmucosal buprenorphine for the treatment of opioid use disorder, extended-release buprenorphine was not associated with efficient allocation of limited resources when transmucosal buprenorphine was available. Future initiatives should aim to improve retention rates or decrease costs associated with extended-release buprenorphine.
Authors: Juliet M. Flam-Ross, B.A., of the London School of Hygiene and Tropical Medicine in London, and Sabrina A. Assoumou, M.D., M.P.H., of the Boston Medical Center in Boston, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.29583)
